Comparison of Intravitreal Bevacizumab and Triamcinolone with Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Phase 2
- Conditions
- Anterior Ischemic of Optic Nerve.Disorders of optic nerve, not elsewhere classified
- Registration Number
- IRCT1138901221180N13
- Lead Sponsor
- Ophthalmic Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days). Exclusion criteria: any eye disease except NAION (Nonarteritic Anterior Ischemic Optic Neuropathy), neurologic defect, abnormal ESR, CRP, any history of retina or vitrea surgery, severe corneal opacity which makes retina examination impossible.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BCVA. Timepoint: 1,3, 6 months. Method of measurement: snellen chart.
- Secondary Outcome Measures
Name Time Method Visual field. Timepoint: 1,3,6 months. Method of measurement: snellen.